A guardian molecule ensures that liver cells do not lose their identity. This has been discovered by researchers from the ...

Long classified as a subset of common liver cancer, FLC should be considered ... coupled with a just-launched clinical trial of a promising drug treatment, could significantly improve health ...

Researchers describe successful tumor removal through the use of immunotherapy and targeted radiation therapy (TARE), in a patient previously considered ineligible for the procedure.

TheraBionic is the only FDA-approved therapy indicated in liver cancer patients that fail first-line and second-line therapy, so that's really the place it takes right now in 2025. Patients can ...